NEXVET ANNOUNCES US$31.5 MILLION FINANCING

NEXVET ANNOUNCES US$31.5 MILLION FINANCING U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia–April 16, 2014 –Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top–‐tier U.S.–‐based institutional investors Farallon Capital Management, LLC, Adage […]

Avita Medical – ReCell containing ambient-stored enzyme launched in United Kingdom and europe

Australia, 8 April 2014 – Link here. NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 8 April 2014 – Regenerative medicine company Avita Medical Limited “Avita Medical” (ASX:AVH), (OTCQX:AVMXY) is pleased to advise that it has developed and released to market a new version of ReCell® ‘Spray‐on Skin®’ that no longer requires refrigeration. This greatly improves the commercial and […]

Nexvet shares promise of new treatments for chronic illness in companion animals with BSAVA Congress 2014

Link here. BIRMINGHAM, United Kingdom –‐ April 3, 2014 – Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that its Chief Scientific Officer, Professor David Gearing, will be presenting at the British Small Animal Veterinary Association (BSAVA) Congress 2014. The BSAVA Congress runs from April 3 – 6 and is one of Europe’s largest […]

SeaDragon Investor Update March 2014

SEA:NZX MARKET UPDATE 1 April 2014 SeaDragon Investor Update March 2014 (Link here). SeaDragon, Australasia’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils, today releases its investor update. The update includes: • an update on trading; • significant growth in squalene business following the execution of a raw […]